Clinical trials

The purpose of this research study is to see if ABBV-400 has any benefits at dose levels thought to be acceptable in earlier studies. The researchers want to find out what effects (good and bad) ABBV-400 has on metastatic colorectal cancer.

The goal of this study is to determine the optimal dose level for the study drug ABBV-400 in combination with 5-FU, folinic acid, and bevacizumab to define the recommended Phase 3 dosage regimen for the combination and to evaluate the efficacy (how well the study drug works), safety and tolerability of the study drug in patients with unresectable metastatic colorectal cancer who have received prior therapy for this colorectal cancer and have progressed during or after the prior treatment.

The study is designed to examine difference the between two standard of care antibiotic regimens with a secondary aim to determine if the different antibiotic regimens could differ by race.

This study aims to assess whether a 3-week hypofractionated proton radiation therapy regimen for breast cancer, targeting the breast/chest wall and regional lymph nodes, is as effective as a traditional 5-week regimen in terms of skin and soft tissue side effects. Specifically, it seeks to determine if the shorter treatment duration results in comparable rates of both acute and late side effects when compared to the longer, conventionally fractionated proton therapy schedule.

Single arm- triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of hepatocellular carcinoma.
Assessing the objective response rate (ORR) at 6 months in patients with unresectable, locally advanced or metastatic HCC.
The Objective Response Rate (ORR) in terms of tumor shrinkage (by RECIST v1.1 criteria) obtained during the treatment with protocol therapy.

This phase II MyeloMATCH treatment trial compares cytarabine with daunorubicin versus cytarabine with daunorubicin and venetoclax versus venetoclax with azacitidine for the treatment of younger patients with intermediate risk acute myeloid leukemia (AML). Cytarabine is a drug that inhibits some of the enzymes needed for deoxyribonucleic acid (DNA) replication and repair and can slow or stop the growth of cancer cells. Daunorubicin is a drug that blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Azacitidine is a drug that interacts with DNA to activate tumor-suppressing genes, resulting in an anti-tumor effect. Adding venetoclax to cytarabine and daunorubicin, and adding venetoclax to azacitidine, may work better than the usual treatment of cytarabine with daunorubicin alone. To decide if they are better, the study doctors are looking to see if venetoclax increases the rate of elimination of AML in participants by 20% or more compared to the usual approach.

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have.

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and overall survival (OS), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants.

To evaluate the safety and tolerability of LNCB74. To determine the maximum tolerated dose (MTD), maximum administered dose (MAD) and/or recommended Phase 2 dose (RP2D) of LNCB74. 

The purpose of this study is to see if sacituzumab govitecan in combination with pembrolizumab can improve outcomes and delay the return of disease in participants with high-risk early triple-negative breast cancer (TNBC) when compared to pembrolizumab alone or pembrolizumab in combination with capecitabine.